CLVS Clovis Oncology, Inc.

55.04
-0.44  -1%
Previous Close 55.48
Open 55.90
Price To book 14.26
Market Cap 2.46B
Shares 44,772,000
Volume 744,006
Short Ratio 3.65
Av. Daily Volume 1,748,200

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Pivotal trial initiated late 2013. Enrolment completed 2Q 2016. Data due June 2017.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Rociletinib
Mutant EGFR T790M-positive lung cancer
Development discontinued
Lucitanib
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line

Latest News

  1. Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting
  2. Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain
  3. Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug?
  4. Edited Transcript of CLVS earnings conference call or presentation 3-May-17 8:30pm GMT
  5. How Clovis Might Still Quash AstraZeneca, Tesaro In Cancer
  6. Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update
  7. Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start
  8. Clovis reports 1Q loss
  9. Clovis Oncology Announces First Quarter 2017 Operating Results
  10. Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment
  11. Tesaro Inc Bulls Need a Reality Check
  12. Tesaro's Path to a Billion-Dollar Blockbuster Begins With Pricing
  13. Tesaro’s Zejula Flops as H&S Pattern Emerges
  14. Tesaro Dives On 'Sticker Shock' For $177,000 Drug
  15. AbbVie's PARP Inhibitor Comes Up Empty
  16. Clovis Oncology to Announce First Quarter 2017 Financial Results and Host Webcast Conference Call on May 3
  17. 3 Cancer Drug Stocks That Could Make You Rich
  18. Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology
  19. Why Clovis Oncology's Stock Edged Higher in March
  20. Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : March 31, 2017